About this item:

107 Views | 44 Downloads

Author Notes:

Dr. Harvey has served as a consultant to Amgen and GlaxoSmithKline and has received institutional research funding from Abbisko Therapeutics, AbbVie, Actuate, Alkermes, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Biomedical, Calithera, FujiFilm, Genmab, GlaxoSmithKline, Infinity, InhibRx, Janssen, Lycera, Merck, Mersana, Meryx, Nektar, Pfizer, Puma Biotechnology, Rapt Therapeutics, Regeneron, Rgenix, Sanofi, Seattle Genetics, Sutro, Takeda, and Xencor. Mr. Begue and Mr. Raine have no conflicts of interest to disclose. Dr. Yabroff has served on the health equity advisory board of Flatiron Health.

Subjects:

Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective.

Tools:

Journal Title:

J Adv Pract Oncol

Volume:

Volume 13, Number 3

Publisher:

, Pages 198-201

Type of Work:

Article | Final Publisher PDF

Abstract:

At the opening session of JADPRO Live Virtual 2021, panelists shared creative responses to the COVID-19 pandemic and considered strategies to effectively respond to crises that may impact cancer patients and practices in the future.

Copyright information:

© 2022 Harborside™

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/rdf).
Export to EndNote